


Fatty Acid and Retinol-Binding Protein: Unusual Protein Conformational and Cavity Changes Dictated by Ligand Fluctuations

G. P. Barletta,[†] G. Franchini,[‡] B. Corsico,[‡] and S. Fernandez-Alberti^{*,†}

[†]Universidad Nacional de Quilmes/CONICET, Roque Saenz Peña 352, B1876BXD Bernal, Argentina

[‡]Instituto de Investigaciones Bioquímicas de La Plata, CONICET-UNLP, Facultad de Ciencias Médicas, calles 60 y 120 s/n, 1900 La Plata, Argentina

S Supporting Information



ABSTRACT: Lipid-binding proteins (LBPs) are soluble proteins responsible for the uptake, transport, and storage of a large variety of hydrophobic lipophilic molecules including fatty acids, steroids, and other lipids in the cellular environment. Among the LBPs, fatty acid binding proteins (FABPs) present preferential binding affinities for long-chain fatty acids. While most of FABPs in vertebrates and invertebrates present similar β -barrel structures with ligands accommodated in their central cavity, parasitic nematode worms exhibit additional unusual α -helix rich fatty acid- and retinol-binding proteins (FAR). Herein, we report the comparison of extended molecular dynamics (MD) simulations performed on the ligand-free and palmitic acid-bound states of the *Necator americanus* FAR-1 (Na-FAR-1) with respect to other classical β -barrel FABPs. Principal component analysis (PCA) has been used to identify the different conformations adopted by each system during MD simulations. The α -helix fold encompasses a complex internal ligand-binding cavity with a remarkable conformational plasticity that allows reversible switching between distinct states in the holo-Na-FAR-1. The cavity can change up to one-third of its size affected by conformational changes of the protein–ligand complex. Besides, the ligand inside the cavity is not fixed but experiences large conformational changes between bent and stretched conformations. These changes in the ligand conformation follow changes in the cavity size dictated by the transient protein conformation. On the contrary, protein–ligand complex in β -barrel FABPs fluctuates around a unique conformation. The significantly more flexible holo-Na-FAR-1 ligand-cavity explains its larger ligand multiplicity respect to β -barrel FABPs.

1. INTRODUCTION

Hydrophobic lipophilic molecules like fatty acids, steroids, retinoids, and their derivatives participate in a large variety of functions within a cell, including energy storage, signaling, regulation of gene expression, hormonal roles, and membrane permeability regulation among others. Their insolubility in water and their potential oxidative degradation require their coordinated transport and availability, protection and regulation throughout the hydrophilic intracellular environment. Soluble lipid-binding proteins (LBPs) are a group of abundant proteins that are responsible for these tasks throughout the aqueous environment inside numerous types of cells¹ and body fluids of different organisms.² Helminth parasites have a restricted lipid metabolism and must acquire simple and complex lipids from their hosts,³ therefore LBPs probably

perform very important functions for parasite growth and development.

Fatty acid and retinol binding proteins (FARs) are LBPs that have been described as components of E/S fluids from parasitic nematodes^{4–7} and they are hypothesized to play essential roles in lipid acquisition and distribution of nutrients as well as potential dampening of host's immune response.^{8,9} FARs together with nematode polyprotein/allergens (NPAs)¹⁰ are small (14–20 kDa), helix rich proteins that bind retinol and fatty acids and have no recognizable counterparts in other animal groups.² Given these characteristics, FARs have been proven to be useful for serodiagnosis and experimental

Received: April 29, 2019

Published: July 31, 2019

50 vaccines.^{11–13} Moreover, there is evidence that FARs from
51 filarial nematodes are able to bind anthelmintic drugs.^{14,15}

52 Hookworm disease is a highly debilitating helminth infection
53 that is related to iron deficiency anemia (IDA) in tropical
54 developing countries with an estimated prevalence of 451
55 million cases that cause 1.6 million years lived with disability
56 (YLD).¹⁶ *Necator americanus*, together with *Ancylostoma*
57 *duodenale* and *Ancylostoma ceylanicum*, are the causative agents
58 for the above mention “hookworm disease”. It is important to
59 note that *N. americanus* is responsible for the majority of cases
60 worldwide. This parasitosis has been successfully eradicated
61 from developed countries by mass drug treatments and by
62 economic development.¹⁷ Nevertheless the levels of disease
63 burden remains high in many low middle income countries like
64 the north region of Argentina.¹⁸

65 FARs occur in several isoforms, and Na-FAR-1 has been
66 found to be highly expressed in the adult form.^{19,20} At the
67 present time, two orthologues FAR structures were solved, one
68 from *Necator americanus* (Na-FAR-1 by protein nuclear
69 magnetic resonance (NMR) and X-ray crystallography; PDB:
70 4UET and 4XCP, respectively)²⁰ and another from *Caeno-*
71 *rhabditis elegans* (Ce-FAR-7, by X-ray crystallography; PDB:
72 2W9Y).²¹ Both present similar overall α helix-rich structures
73 with certain structural differences. Particularly, the size and
74 shape of their internal cavities are different, denoting
75 differences in their ligand selectivity. Na-FAR-1, in either its
76 apo- and holo-conformations, presents a larger and more
77 complex internal ligand-binding cavity.²⁰

78 Among soluble LBPs, another interesting group is the fatty
79 acid binding proteins (FABPs) family presenting preferential
80 binding affinities for long-chain fatty acids.^{22–27} While FARs
81 have been found exclusively in nematodes²⁸ FABPs can be
82 found in vertebrates and invertebrates. Despite their low
83 sequence identity and their functional divergence, probably
84 related to their particular lipid-binding preferences, they share
85 a common tertiary structure.^{29,30} They all have similar β -barrel
86 structures that encase the bound fatty acid. The volume of the
87 inner ligand-binding cavity is determined by the side chains of
88 the residues that define the molecular surface enclosing it.
89 These residues vary between the different FABP types, and
90 they determine the ligand specificity of the cavity. Various
91 single point mutations, performed on residues lining the cavity
92 of different FABP types, have shown to modify the protein
93 conformational stability, ligand specificity and affinity.^{31–36}

94 Several studies, based on crystal and solution analysis,
95 predicted the way FAs enter and leave the FABP binding
96 site;^{24,37} this is fundamental to understanding the molecular
97 mechanism of ligand selection and delivery in FABPs.^{38,26,39–42}
98 These works have shown the importance of certain residues
99 and domains in the protein dynamics, confirming observations
100 performed by different experimental methods and allow to
101 hypothesize about these protein’s proposed functions in the
102 cell. While nematodes also produce β -barrel FABPs, the
103 reasons why nematodes have specialized in the use of α -helix
104 rich proteins remain unclear.

105 An understanding of how the conformational diversity of
106 FARs contributes to their ligand multiplicity, varying the
107 relative affinities for different hydrophobic lipophilic mole-
108 cules, could enlighten their roles in parasitism and suggest
109 possible targets for therapeutic interventions. Fluorescence-
110 based ligand-binding assays and titration of Na-FAR-1 with
111 sodium oleate monitored by NMR reveal its high ligand
112 multiplicity.²⁰ These studies suggest the higher propensity of

the α -helical fold to bind a larger variety and quantity of FAs
113 and other lipid classes than the β -barrel fold. Besides, Na-FAR-
114 1 ligand-binding induces substantial chemical shift changes for
115 residues throughout the protein, indicating significant con-
116 formational changes that allow the structure to expand.

117 Molecular dynamics (MD) simulations^{43–46} combined with
118 principal component analysis (PCA)^{47–51} provide a framework
119 for decomposing the complexity of proteins motions into
120 decoupled individual contributions. PCA is a useful multi-
121 variate statistical method that has been applied to reduce the
122 number of dimensions needed to describe protein dynamics.
123 This combination of MD and PCA has recently been applied
124 to develop a procedure that reveals the existence of
125 correlations between the dynamics of cavities and struc-
126 tures.^{52,53} Besides, MD simulations have shown to be the
127 adequate computation method to reveal several dynamic and
128 functional aspects of LBPs,^{54,55,40,56} like ligand entry and leave
129 pathways and complex formation,^{26,39,57} and binding-relevant
130 intermediate states.⁴² Moreover, MD simulation of the
131 flexibility of the internal cavity has shown to be a requirement
132 for a good simulation of ligand-LBPs affinities.⁵⁸

133 Herein we explore the structure-dynamics-function relation-
134 ship of Na-FAR-1 using long molecular dynamics simulations
135 combined with PCA in its *apo*- and *holo*-forms. We analyze its
136 plasticity and the impact of the different conformations on the
137 ligand-binding cavity volume. We were focused on the
138 dynamics relationships between protein fluctuations, cavity
139 changes, and the enclosed ligand different conformations. A
140 comparison of our results with those obtained from MD
141 simulations of the rat intestinal fatty-acid-binding protein (I-
142 FABP) with the typical FABP β -barrel fold, and the orthologue
143 Ce-FAR-7 is performed. Our analysis reveals that Na-FAR-1
144 encompasses a complex internal ligand-binding cavity with a
145 remarkable conformational plasticity that allows reversible
146 switching between distinct states according with the enclosed
147 ligand different conformations. 148

2. METHODS

2.1. Molecular Dynamics simulations. Molecular
149 dynamics (MD) simulations were performed for Na-FAR-1
150 and I-FABP, both in their *apo*- and *holo*- forms with palmitate
151 in their binding pockets, and Ce-FAR-7 in its unligated form.
152 These were carried out with AMBER 16 software package.^{59,60}
153 Initial structures for each protein were obtained from the
154 protein data bank⁶¹ (pdb id 4UET (no. of atoms = 23173) and
155 4XCP (no. of atoms = 22707) for *apo*- and *holo*-Na-FAR-1²⁰
156 respectively, 1IFB⁶² (no. of atoms = 15502) for *apo*-I-FABP,
157 2IFB⁶³ (np. of atoms = 15768) and 1URE⁶⁴ (no. of atoms =
158 16143) for *holo*-I-FABPs and 2W9Y²¹ (no. of atoms 21528)
159 for *apo*- Ce-FAR-7). Each protein was solvated with explicit
160 water molecules in a rectangular periodic box large enough to
161 contain the protein and 10 Å of solvent on all sides. Ions are
162 added for charge neutralization. Periodic boundary conditions
163 and particle-mesh Ewald (PME) sums were applied. The
164 AMBER ff14SB^{65,66} force field and the TIP3P⁶⁷ water model
165 were used in all simulations. Minimization of each system was
166 performed in two steps: first, constraints were applied to the
167 protein atoms and 200-steps of steepest-descent and 800-steps
168 of conjugate gradient minimization were run; then, constraints
169 are lifted and the same procedure were applied again. This was
170 followed by 400 ps of heating to reach the final temperature of
171 300 K. During heating a harmonic constraint of 25.0 (kcal/
172 mol)/Å² was applied to the protein atoms. The time step was 2 173




Figure 1. Averaged (b) *apo*- and (d) *holo*-structures for Na-FAR-1 obtained from the corresponding equilibrated MD simulations, indicating the main secondary structure elements (SSE) and the encompassed ligand cavity. Distribution of ligand cavity volumes, calculated over the set of structures collected during the equilibrated MD simulations of (a) *apo*- and (c) *holo*-Na-FAR-1.

174 fs, and the SHAKE algorithm was employed to constrain bonds
175 involving hydrogen atoms. A cutoff of 10 Å was applied to
176 nonbonded interactions. Systems were equilibrated for 7.8 ns
177 at constant pressure gradually reducing the constraints every
178 100 ps until all restraints were lifted. After that, the systems
179 were equilibrated at the constant temperature of 300 K using
180 the Andersen barostat and the Langevin thermostat with a γ
181 collision frequency of 2 ps⁻¹ during 12.2 ns. Finally, 3- μ s
182 production MD runs were performed, during which config-
183 urations were collected at 10 ps intervals.

184 **2.2. Principal Component Analysis.** PCA is an
185 extensively used statistical procedure to identify the essential
186 dynamics from MD simulations^{47–51,68} and, thereby, facilitate
187 the study of long time dynamics. For the sake of consistency,
188 we briefly review PCA below.

189 Herein, PCA modes \mathbf{Q}_i are $3N$ orthogonal eigenvectors
190 obtained as columns of the eigenvector matrix \mathbf{L} , that results
191 after diagonalizing ($\mathbf{L}^T \mathbf{C} \mathbf{L} = \mathbf{\Lambda}$) the covariance matrix of
192 atomic fluctuations \mathbf{C} whose elements are defined as

$$C_{ij} = \langle q_i q_j \rangle = \frac{1}{K} \sum_{k=1}^K q_i^k q_j^k \quad (1)$$

193 where the sum goes over the K configurations stored during
194 previously equilibrated MD simulations, $q_i^k = \sqrt{m_i}(x_i^k - \langle x_i \rangle)$
195 is the mass-weighted internal displacement of Cartesian
196 coordinate x_i^k of the i th atom ($i = 1, \dots, N$; $N =$ number of
197 residues in the protein (C_α) with mass m_i , and the angular
198 brackets represent the average obtained from the K
199 configurations.⁶⁸ The elements of the diagonal matrix $\mathbf{\Lambda}$
200 represent the relative contribution of each PCA or essential
201 mode (EM) to the overall fluctuation of the molecule. The
202 eigenvectors are typically ordered according to descending
203 eigenvalues, with the first PCA mode being the one with major
204 contribution.

205 **2.3. Ligand-Cavities: Definition, Volume, and Flexi-**
206 **bility.** Ligand-cavities have been defined by visual inspection
207 of the average of equilibrated MD structures and previous
208

knowledge on each system. The complete list of residues lining 209
the main ligand-binding cavity for each system is provided in 210
the [Supporting Information](#) (Table S1). 211

Cavity volumes are calculated using our previously 212
developed method,⁵³ particularly suited to measure changes 213
in cavity volumes due to small atomic coordinate displace- 214
ments in the direction of specific predefined directions of 215
protein structural displacements. Following our previous works 216
we make use of the volume gradient vector (∇V_{ol}), defined as 217
the vector of partial derivatives of the cavity volume in the 218
basis of PCA modes $\{\mathbf{Q}_i\}_{i=1,3N}$, that is 219

$$\nabla V_{ol} = \sum_{i=1}^{3N} c_i \mathbf{Q}_i = \sum_{i=1}^{3N} \frac{\partial V_{ol}}{\partial Q_i} \mathbf{Q}_i \quad (2) \quad 220$$

Within the frame of the quasi-harmonic analysis approx- 221
imation,⁶⁹ the variation of the potential energy of a protein in 222
the direction of ∇V_{ol} is defined as 223

$$\nabla E_{\nabla V_{ol}} = \sum_{i=1}^{3N} \Delta E_{\mathbf{Q}_i} \quad (3) \quad 224$$

with 225

$$\Delta E_{\mathbf{Q}_i} = \frac{1}{2} k_i c_i^2 \Delta X^2 \quad (4) \quad 226$$

being $k_i = \frac{k_B T}{\lambda_i}$, k_B the Boltzmann constant and T the absolute 227
temperature (300 K). ΔX represents a relative displacement in 228
the direction of ∇V_{ol} . Therefore, we consider $\Delta E_{\nabla V_{ol}}$ as 229
measure of flexibility of the cavities. 230

3. RESULTS AND DISCUSSION

3.1. α -Helix Rich FARs. While most of FABPs present a β - 231
barrel folding, FARs reveals an unusual α -helical fold. In the 232
case of Na-FAR-1, it consists of a wedge-shaped structure 233
composed of 11 helices with different lengths that enclose an 234
internal ligand-binding cavity. The overall ligand-binding 235
conformational change involve a global RMSD of 0.98 Å 236

237 between conformers, calculated from the α -carbons super-
 238 position of averaged *apo*- and *holo*-structures obtained from the
 239 corresponding equilibrated MD simulations (see Figure 1b,d).
 240 Both *holo*-states for Na-FAR-1 and I-FABP are bound to a
 241 single molecule of palmitate. It is important to note that this is
 242 the preferred ligand of Na-FAR-1 in a biological environment²⁰
 243 The main structural distortions upon ligand binding are
 244 localized on helices 3_{10} , $\alpha 2$, $\alpha 7$, $\alpha 10$ and the loops between 3_{10} -
 245 $\alpha 2$, $\alpha 2$ - $\alpha 3$, $\alpha 4$ - $\alpha 5$, and $\alpha 7$ - $\alpha 8$. Among these Secondary
 246 Structure Elements (SSE), $\alpha 4$ - $\alpha 5$ and $\alpha 7$ - $\alpha 8$ have shown the
 247 largest root-mean-square fluctuations (RMSF; see Figure S1)
 248 during our MD simulations, particularly residues 39–45 in $\alpha 4$ -
 249 $\alpha 5$ loop and residues 100–103 in $\alpha 7$ - $\alpha 8$ loop present the
 250 largest relative flexibility. The structural change of $\alpha 4$ - $\alpha 5$ loop
 251 during ligand-binding is expected since this loop is part of the
 252 single opening of the ligand-binding cavity, located between
 253 this loop and helices $\alpha 6$ and $\alpha 7$. Besides this opening, $\alpha 7$ - $\alpha 8$
 254 loop has been previously proposed²⁰ as the main candidate to
 255 participate of the ligand entrance through the portion of the
 256 cavity accessible to solvent.

257 At this point it is interesting to note that the RMSD between
 258 average *holo*- and *apo*- structures of Na-FAR-1 is only 1.58 Å.
 259 Nevertheless, in a previous article,⁷⁰ we have pointed out that
 260 small structural distortions can involve large changes in the
 261 cavities of the proteins. Besides, in cases that proteins explore
 262 multiple conformers during MD simulations, the average
 263 structural is not a good statistics. Therefore, in what follows,
 264 the identification of different conformers and their impact on
 265 the ligand-cavity is discussed.

266 A further inspection of the internal ligand-binding cavity can
 267 be seen in Figure 1a,c where the distributions of cavity
 268 volumes, calculated over the set of structures collected during
 269 the equilibrated MD simulations of *apo*- and *holo*-Na-FAR-1,
 270 are shown. Their average values are 1353 ± 254 and $1397 \pm$
 271 266 \AA^3 respectively. These values differ from the corresponding
 272 940 and 2170 \AA^3 calculated on the initial experimental
 273 structures.²⁰ As we have pointed out previously, we define
 274 internal cavities according to average structures obtained from
 275 our MD simulations. The distributions shown in Figure 1a,c
 276 are the result of the protein thermal fluctuations that can
 277 involve different conformational changes throughout the 3- μ s
 278 of MD simulations. Fluctuations of helices that form the cavity
 279 introduce relatively small protein structural rearrangements
 280 that can lead to significant changes on the internal cavity size.⁷⁰
 281 Histograms shown in Figure 1a,c reveal that internal cavity can
 282 duplicate its volume due to protein fluctuations. While the
 283 distribution of volume cavities for *apo*-Na-FAR-1 corresponds
 284 to a Gaussian distribution that can be associated with thermal
 285 fluctuations around a unique protein conformation, this is not
 286 the case for *holo*-Na-FAR-1.

287 Volume cavity changes can be associated with protein
 288 fluctuations. Therefore, in order to elucidate this feature, MD
 289 simulations were analyzed in terms of PCA. The first and
 290 second PCA modes of *apo*- and *holo*-Na-FAR-1 are shown in
 291 Figure 2a,b. In both conformers, the first 2 modes involve the
 292 concerted motion of residues located in helices $\alpha 4$, $\alpha 5$, the
 293 loop between, and the C-term of the helix $\alpha 7$. In agreement
 294 with previous experimental observations,²⁰ the last helix has
 295 the most impact on cavity volume, while the former form the
 296 ligand entrance gate ($\alpha 4$ - $\alpha 5$ gate).

297 Figure 3a,b show the projection of the set of MD snapshots
 298 of *apo*- and *holo*-Na-FAR-1 onto their corresponding first and
 299 second PCA modes. Thermal fluctuations of *apo*-Na-FAR-1 are




Figure 2. 1st (red) and 2nd (blue) PCA modes of (a) *apo*- and (b) *holo*-Na-FAR-1.




Figure 3. Contour density plots of the projection of the set of MD snapshots of (a) *apo*- and (b) *holo*-Na-FAR-1 onto their corresponding 1st and 2nd PCA modes.

revealed as gradual combinations of both modes without 300
 showing significant prevalence of structural distortions in any 301
 specific direction. That is, *apo*-Na-FAR-1 does not visit any 302
 new conformation that persists a significant amount of time 303
 during the MD simulation. On the contrary, we can observe 304
 that *holo*-Na-FAR-1 actually evidence the existence of three 305
 different conformers: two stable conformers presenting 306
 structural distortions mainly in both senses of the direction 307
 of the first PCA mode (conformers A and B), and a third 308
 conformer C in the direction of the second PCA mode. The 309
 projections of the set of MD snapshots of *apo*- and *holo*-Na- 310
 FAR-1 onto their corresponding third PCA modes do not 311
 show the existence of new stable conformers with structural 312
 distortions in the direction of these modes (see Figure S2). 313
 The major differences among conformers A, B, and C lie in the 314
 $\alpha 4$ - $\alpha 5$ gate and the helix $\alpha 7$. Conformer A's $\alpha 7$ helix is 315
 relatively straightened, allowing the $\alpha 4$ - $\alpha 5$ gate to close up. B's 316
 $\alpha 7$ helix has a kink next to its C-term around ILE 104, which 317
 displaces the $\alpha 4$ - $\alpha 5$ gate. This kink is even steeper in 318
 Conformer C. This kink is the main reason for the volume 319
 decrease in conformers B and C (see Figure 4a). Therefore, 320
 the distribution of internal cavity volumes shown in Figure 1c 321
 can be interpreted as the contribution of three different 322
 conformations explored by *holo*-Na-FAR-1 during the MD 323




Figure 4. (a) Superposition of the three conformers (A, B, and C) of holo-Na-FAR-1; (b) distribution of cavity volumes for each of the conformers (A, B, and C) of holo-Na-FAR-1 during the MD simulation; (c) evolution in time of the cavity volume displaying the different contributions of each of the three A, B, and C conformers.

simulation. Figure 4b shows the distribution of cavity volumes for each of them. While two of the holo-Na-FAR-1 conformers (B and C) enclose relative small internal cavities with average volumes of 1130 ± 126 and $1211 \pm 150 \text{ \AA}^3$, the other conformer (A) presents a large cavity of $1568 \pm 222 \text{ \AA}^3$. These results indicate that holo-Na-FAR-1 presents a remarkable conformational plasticity that drives a complex internal cavity dynamics. The three identified conformers are in dynamical equilibrium connected by conformational changes involving the first and the second PCA modes. Figure 4c shows the evolution in time of the cavity volume displaying the different contributions of each of the three conformers. Reversible interconversions between them can be observed during the MD simulation. These results are in complete agreement with our previous analysis of the apo and holo structures of Na-FAR-1 employing NMR spectroscopy.²⁰ In the referred work, NMR spectra of holo-Na-FAR-1 in solution, like those of other FAR proteins previously tested, were characterized by broad signal peaks indicative of multiple conformations and/or conformational exchange. However, apo-Na-FAR-1 gave good solution NMR spectra which allowed the structure of apo-Na-FAR-1 to be determined. In the same work the ligand binding process was followed through NMR and showed that the protein exhibited slow exchange behavior through the addition of 1, 2, and 3 mol equiv of the ligand (oleate), which would suggest that the protein binds three ligands with high affinity. The higher plasticity of the protein after the incorporation of one molecule of ligand, as shown in the present work, would

eventually make the protein more susceptible to accept more ligand molecules.

In order to further understand the effect of higher conformational plasticity of holo-Na-FAR-1 respect to apo-Na-FAR-1 on the ligand binding, the dynamics of the ligand within the cavity has been explored. For this purpose, ligand structural fluctuations have been analyzed using PCA. Figure 5(a) shows the projection of the ligand structures, obtained




Figure 5. (a) Contour density plots of the projection of the palmitate structures, obtained from the set of MD snapshots of holo-Na-FAR-1, onto its 1st and 2nd PCA modes; (b) distribution of cavity volumes according to the conformation of the ligand encompassed in it; (c) evolution in time of the cavity volume displaying the different conformations adopted by the ligand.

throughout the MD simulation, onto its first and second PCA modes. Two distinctive ligand conformations represented by the structural distortions in both senses of the direction of the first PCA mode can be observed. They correspond to the bent and stretched conformations shown in Figure 5a. As can be seen in Figure 5b, the ligand fluctuates between them, being the stretched conformation associated with large cavity volumes while the bent one is observed within smaller cavity volumes (Figure 5c). That is, far from being fixed within the cavity, the ligand experiences large conformational changes associated with changes of cavity volume.

The relationship between the different holo-Na-FAR-1 conformers, with their corresponding associated changes in the internal cavity volume, and the different ligand conformations can be analyzed by depicting the distribution of distances between the extremes of the palmitate molecule, that is, the distance from the C atom of carboxyl group to the C atom of the methyl group (see Figure 6). We can observe that the stretched palmitate conformation is associated with the holo-Na-FAR-1 conformer (A) with the largest internal cavity and the straightened $\alpha 7$ helix to make room for the




Figure 6. Distribution of distances between the extremes of the palmitate molecule for each of the conformers (A, B, and C) of *holo*-Na-FAR-1 during the MD simulation.

381 ligand, while the bent conformation is mainly present on the
382 other two conformers (B and C). Since the three *holo*-Na-
383 FAR-1 conformers are in dynamics equilibrium during the MD
384 simulation (see Figure 4c), the ligand changes its conformation
385 accordingly to the corresponding changes in the cavity sizes
386 associated with each protein conformational change.

387 Finally, MD simulations have been performed on the
388 orthologue Ce-FAR-7 in its *apo*-conformation. Figure 7b
389 shows the average structure obtained from the corresponding
390 equilibrated MD simulation. Ce-FAR-7 is an orthologue of Na-
391 FAR-1 that, despite its similar overall fold, it presents an
392 internal cavity different in size and shape respect to Na-FAR-
393 1.²⁰ Therefore, a comparison of the relative flexibility of the
394 ligand-binding cavities for Ce-FAR-7 and Na-FAR-1 can
395 enlighten on the origin of the differences in their ligand
396 binding and biological properties.

397 The RMSD between average *apo*-Na-FAR-1 and *apo*-Ce-
398 FAR-7 is 2.77 Å. In agreement with *apo*-Na-FAR-1, Figure 7a
399 shows that the distribution of its internal cavity volume can be
400 associated with protein fluctuations around a unique
401 conformation characterized by a free energy landscape with a
402 relatively deep well. These results are in agreement with the
403 observations made by Rey-Burusco et al.²⁰ where the estimated
404 cavity for Ce-FAR-7 calculated revealed a much smaller size
405 than for both forms of Na-FAR-1.

406 **3.2. β -Barrel FABPs.** While FARs exhibit α -helix rich folds,
407 most FABPs present a typical FABP β -barrel fold that includes
408 a small and displaced hydrophobic core and a cavity filled with
409 water molecules. In order to understand how the different folds
410 impact on the protein properties associated with the transport
411 of a variety of ligands with different shapes and sizes, MD
412 simulations have been performed on the rat intestinal fatty-
413 acid-binding protein (I-FABP) in its *holo* and *apo* forms. The
414 ligand-binding conformational change involves a structural

distortion with a RMSD = 1.00 Å. The average internal ligand-
cavity is significantly smaller than Na-FAR-1, being 605 ± 145
and $926 \pm 85 \text{ \AA}^3$ for *apo*-I-FABP and *holo* I-FABP respectively
(see Figure 8). We can observe that the distribution of cavity
volumes for *apo*-I-FABP can be associated with the
contribution of different conformations explored during the
MD simulation. On the contrary, ligand-binding funnels *holo*-I-
FABP onto a unique rigid state. These results are in good
agreement with previous NMR measurements performed on
human L-FABP⁷¹ and rat I-FABP⁷² that describe ligand
binding as a transition of the protein structure from a slightly
more disordered and flexible *apo*-state to a more ordered *holo*-
state. Additionally, limited proteolysis experiments performed
on apo- and holo- rat IFABP showed that the holo-form was
resistant to overnight treatment while apo-IFABP was fully
degraded.^{73,74} This analysis have also been applied on cestodes
FABPs yielding the same result.⁷⁵ Besides, the comparison of
RMSF obtained during our MD simulations indicates larger
fluctuations for the *apo*- than for the *holo*- I-FABP (see Figure
S1). This is in good agreement with the results of Matsuoka et
al.⁴⁰ where the authors show that the calculated RMSF values
were less than 1.0 Å for almost all protein residues, indicating
that this protein is rigid in the ligand-bound form. This
increased mobility and discrete disorder in the *apo*-state may
facilitate the entry of the ligand into the cavity.

PCA allows the identification of the different *apo*-I-FABP
conformers and their corresponding effect on the volume of
the internal cavity (see Figure 9a,b). Four different conformers,
associated with different combinations of structural distortions
in the directions of the first and second PCA modes, have been
identified (see also Figure S3 and Figure S4). Two of them (A
and B) are associated with smaller cavity volumes than the
other two (C and D). Figures 9c shows that *apo*-I-FABP
experiences multiple conformational changes throughout the
MD simulation, indicating a relatively low energy barrier
between its states. On the contrary, the projection of the set of
MD snapshots of *holo*-I-FABP onto its first and second PCA
modes does not reveal the existence of multiple conformers
but rather a unique rigid state (see Figure S5). This is in
agreement with the distribution of its cavity volumes, shown in
Figure 8c, represented as a Gaussian distribution that can be
associated with fluctuations around a unique minimum in the
protein conformational space. Ligand binding seems to shift
the conformational equilibrium of I-FABP to a unique
conformation with a sufficiently deep well to ensure that a
significant fraction of protein molecules are trapped fluctuating
in it.

3.3. Relative Flexibility of the Ligand-Cavities. The
different FARs and FABPs analyzed in this study have shown




Figure 7. (a) Distribution of its internal cavity volume, calculated over the set of collected MD structures. (b) Averaged structure of *apo*-Ce-FAR-7 obtained from the equilibrated MD simulation.




Figure 8. Distribution of ligand cavity volumes, calculated over the set of structures collected during the equilibrated MD simulations of (a) *apo*- and (c) *holo*- I-FABP. Averaged (b) *apo*- and (d) *holo*-structures for I-FABP obtained from the corresponding equilibrated MD simulations, indicating the main secondary structure elements (SSE) and the encompass ligand cavity.

464 ligand-cavities with different shapes whose dynamics is subject
 465 to the corresponding protein plasticity. In order to analyze
 466 which LBP fold encompasses a more flexible cavity and,
 467 therefore, a cavity that can contribute to a larger ligand
 468 multiplicity, we calculated the variation of the potential energy
 469 of each LBP in the direction of ∇V_o (see section 2.3). Results
 470 are shown in Figure 10a. We consider the amplitude of the
 471 displacement in the direction of ∇V_o achieved with an energy
 472 equal to $kT = 0.593$ kcal/mol (with k being the Boltzman's
 473 constant and $T = 298$ K) as a measure of flexibility of the
 474 cavity.⁵³ We can observe that the internal cavity of *apo*-I-FABP
 475 results the most flexible one, followed by *holo*- and *apo*-Na-
 476 FAR-1. *Apo*-Ce-FAR-7 presents a relatively more rigid cavity.
 477 Besides, the two *holo*-I-FABPs (1URE and 2IFB) enclose the
 478 most rigid cavities, reinforcing the idea that β -barrel I-FABPs
 479 follow a ligand-binding strategy involving a *holo*-state with
 480 restricted motional freedom.

481 While both *holo*-Na-FAR-1 and *apo*-I-FABP encompass
 482 cavities with different sizes according to the transient protein
 483 conformation, Figure 10b,c displays the analysis of the
 484 corresponding individual conformers. We can observe that,
 485 in both cases, each conformer result relatively more rigid than
 486 the average shown in Figure 10a, indicating that their
 487 individual contributions introduce an additional component
 488 to the overall flexibility of the cavity. Furthermore, *holo*-Na-
 489 FAR-1 conformers are less rigid than the average (see Figure
 490 10b) compared to *apo*-I-FABP conformers relative to their
 491 corresponding average (see Figure 10c). That is, the flexibility
 492 of *holo*-Na-FAR-1 seems to be more uniformly distributed
 493 among the conformer populations in dynamic equilibrium.
 494 Therefore, we conclude that the native state of I-FABP, defined
 495 as an equilibrium of pre-existing populations of states, can be
 496 considered in general more flexible than the native state of I-
 497 FABP. These results indicate a propensity of Na-FAR-1 to bind
 498 not only fatty acids but also a broader range of lipid classes
 499 such as retinol and phospholipids. This feature is in agreement
 500 with previous fluorescence experiments performed on Na-
 501 FAR-1 and Ce-FAR-7.²⁰

4. CONCLUSIONS

Parasitic helminths produce and release an unexpectedly wide
 range of LBPs that are structurally distinct from those of their
 hosts. Although poorly understood, helminth LBPs are often
 immunodominant in infection. Some of them attract allergic-
 type antibody responses and have been associated with
 protective immunity.^{4,76–78} The evolutionary reasons why a
 single species expresses different types of LBPs remain unclear.
 FARs are commonly found in the secretions of parasitic
 nematodes, possibly indicating their role in parasitism.
 Parasites need to acquire nutrients from their hosts and they
 also need to defend themselves against immune response from
 the host. In this sense, it is hypothesized that they interfere by
 sequestering signaling lipids produced by the host. Therefore, a
 large ligand multiplicity of FARs would help in both lipid
 acquisition and sequestering. As mentioned before they have
 also been proven as good vaccine candidates.¹³

Protein fluctuations–cavity changes relationships have been
 explored on different α -helix rich FARs and β -barrel FABPs
 using long equilibrated MD simulations of either *apo*- and *holo*-
 states. We found a significantly flexible Na-FAR-1 ligand-cavity
 that can explain the observed larger ligand multiplicity of α -
 helix FARs respect to β -barrel FABPs. The comparison of the
 relative flexibility of ligand-binding cavities of Ce-FAR-7 and
 Na-FAR-1 reveals how a similar fold can enclose internal
 cavities with significant differences in their flexibilities and
 dynamics. These differences can explain differences in their
 ligand multiplicity and, therefore, their biological function.
 Moreover, differences in ligand binding capacities have been
 observed between two isoforms from the same species.¹³

We have reported two different ligand-binding strategies.
 Particularly, *holo*-Na-FAR-1 presents a remarkable conforma-
 tional plasticity that drives a complex internal cavity dynamics
 involving different states. The size of the cavity is significantly
 affected by protein conformational changes. Besides, the ligand
 also changes its conformation according to these conforma-
 tional changes. That is, far from being fixed within the cavity,




Figure 9. (a) Contour density plots of the projection of the set of MD snapshots of *apo*-I-FABP onto its 1st and 2nd PCA modes; (b) distribution of cavity volumes for each of the *apo*-I-FABP conformers (A, B, C, and D) during the MD simulation; (c) evolution in time of the cavity volume displaying the different contributions of each of the four conformers A, B, C, and D conformers.




Figure 10. Potential energy change in the direction of ∇V_{ol} for each (a) protein structure, (b) *holo*-Na-FAR-1 conformer, and (c) *apo*-I-FABP conformer. The black line indicated as $kT = 0.593$ kcal/mol (with k being the Boltzmann's constant and $T = 298$ K) has been added as reference of the average energy per degree of freedom at room temperature.

538 the ligand experiences large conformational changes between a
539 bent and stretch conformation. The ligand conformation
540 changes according to the size of the cavity that is dictated by
541 the transient protein conformation. On the contrary, ligand
542 binding in I-FABPs seems to shift the conformational
543 equilibrium to a unique conformation. In this way, α -helix
544 FARs and β -barrel FABPs seem to follow two different
545 strategies for ligand-binding. FARs involve a *holo*-state with
546 high plasticity; they experience conformational changes that
547 significantly impact on the cavity volume and embedded ligand
548 conformations. On the other hand, FABPs experience an
549 inverse ligand-modulated disorder–order transition leading to
550 a *holo*-state with restricted motional freedom. This piece of
551 information could give light on the biological reasons for the
552 existence of different LBPs types in the same organism.

553 Human hookworm infections represent a significant
554 problem in South America. There is an urgent need to design
555 new treatments based on the knowledge of the metabolism of
556 the parasites. Na-FAR1 has shown to be part of the excretion/
557 secretion products, playing an important role in the host-
558 parasite relationship. It may participate in the acquisition of
559 lipids from the host or sequestering signaling molecules
560 dampening the immune response from the host. The detailed
561 knowledge of the structural and dynamics properties of its

562 ligand-binding cavity could contribute to the design of new and
563 more specific inhibitors. The flexibility of protein cavities
564 impacts on functional aspects like ligand affinities and binding
565 promiscuities. The present work can encourage the develop-
566 ment of drugs that rigidize the cavity of Na-FAR-1, reducing its
567 ligand multiplicity and, therefore, the efficiency to play its
568 biological function.

■ ASSOCIATED CONTENT

📄 Supporting Information

The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.jcim.9b00364.

Table S1: List of residues lining the main ligand-binding
cavity for each system. Residues are numbered according
to their order in the corresponded PDB file. Figure S1:
Root mean square fluctuations (RMSF) during our MD
simulations. Figure S2: Histogram of the projection of
the set of MD snapshots of *holo*-I-FABP onto its third
PCA mode. Figure S3: First (red) and second (blue)
PCA modes of (a) *apo*- and (b) *holo*-I-FABP. Figure S4:
Superposition of the four conformers (A, B, C, and D)
of *apo*-I-FABP. Figure S5: Contour density plots of the
projection of the set of MD snapshots of *holo*-I-FABP
onto their corresponding first and second PCA modes
(PDF)

586 ■ AUTHOR INFORMATION

587 Corresponding Author

588 *E-mail: sfalberti@gmail.com.589 ORCID 

590 G. P. Barletta: 0000-0002-0806-0812

591 S. Fernandez-Alberti: 0000-0002-0916-5069

592 Notes

593 The authors declare no competing financial interest.

594 ■ REFERENCES

595 (1) Lucke, C.; Gutierrez-Gonzales, L. H.; Hamilton, J. Intracellular
596 Lipid Binding Proteins: Evolution, Structure, and Ligand Binding. In
597 *Cellular proteins and their ligand fatty acids—emerging roles in gene*
598 *expression, health and disease*; Duttaroy, A., Spener, F., Eds.; Wiley:
599 New York, 2003; pp 95–114.

600 (2) Franchini, G.; Pórfido, J.; Ibáñez Shimabukuro, M.; Rey Burusco,
601 M.; Bélgamo, J.; Smith, B.; Kennedy, M.; Córscico, B. The Unusual
602 Lipid-Binding Proteins of Parasitic Helminths and Their Potential
603 Roles in Parasitism and as Therapeutic Targets. *Prostaglandins,*
604 *Leukotrienes Essent. Fatty Acids* **2015**, *93*, 31–36.

605 (3) Barrett, J. Forty Years of Helminth Biochemistry. *Parasitology*
606 **2009**, *136* (12), 1633–1642.

607 (4) Mei, B.; Kennedy, M. W.; Beauchamp, J.; Komuniecki, P. R.;
608 Komuniecki, R. Secretion of a Novel, Developmentally Regulated
609 Fatty Acid-Binding Protein into the Perivittelline Fluid of the Parasitic
610 Nematode, *Ascaris Suum*. *J. Biol. Chem.* **1997**, *272*, 9933–9941.

611 (5) Plenefisch, J.; Xiao, H.; Mei, B. S.; Geng, J. M.; Komuniecki, P.
612 R.; Komuniecki, R. Secretion of a Novel Class of IFABPs in
613 Nematodes: Coordinate Use of the *Ascaris*/*Caenorhabditis* Model
614 Systems. *Mol. Biochem. Parasitol.* **2000**, *105*, 223–236.

615 (6) Garofalo, A.; Rowlinson, M. C.; Amambua, N. A.; Hughes, J. M.;
616 Kelly, S. M.; Price, N. C.; Cooper, A.; Watson, D. G.; Kennedy, M.
617 W.; Bradley, J. E. The FAR Protein Family of the Nematode
618 *Caenorhabditis Elegans* - Differential Lipid Binding Properties,
619 Structural Characteristics, and Developmental Regulation. *J. Biol.*
620 *Chem.* **2003**, *278*, 8065–8074.

621 (7) Jones, J. T.; Kumar, A.; Pylypenko, L. A.;
622 Thiruganasambandam, A.; Castelli, L.; Chapman, S.; Cock, P. J.;
623 Grenier, E.; Lilley, C. J.; Phillips, M. S.; Blok, V. C. Identification and
624 Functional Characterization of Effectors in Expressed Sequence Tags
625 from Various Life Cycle Stages of the Potato Cyst Nematode
626 *Globodera Pallida*. *Mol. Plant Pathol.* **2009**, *10*, 815–828.

627 (8) Kennedy, M. W.; Garside, L. H.; Goodrick, L. E.; McDermott,
628 L.; Brass, A.; Price, N. C.; Kelly, S. M.; Cooper, A.; Bradley, J. E. The
629 Ov20 Protein of the Parasitic Nematode *Onchocerca Volvulus* - a
630 Structurally Novel Class of Small Helix-Rich Retinol-Binding
631 Proteins. *J. Biol. Chem.* **1997**, *272*, 29442–29448.

632 (9) Iberkleid, I.; Vieira, P.; de Almeida Engler, J.; Firester, K.;
633 Spiegel, Y.; Horowitz, S. B. Fatty Acid and Retinol-Binding Protein,
634 Mj-FAR-1 Induces Tomato Host Susceptibility to Root-Knot
635 Nematodes. *PLoS One* **2013**, *8*, e64586.

636 (10) Solovyova, A.; Meenan, N.; McDermott, L.; Garofalo, A.;
637 Bradley, J.; Kennedy, M.; Byron, O. The Polyprotein and FAR Lipid
638 Binding Proteins of Nematodes: Shape and Monomer/Dimer States
639 in Ligand-Free and Bound Forms. *Eur. Biophys. J.* **2003**, *32* (5), 465–
640 476.

641 (11) Fairfax, K. C.; Vermeire, J. J.; Harrison, L. M.; Bungiro, R. D.;
642 Grant, W.; Husain, S. Z.; Cappello, M. Characterisation of a Fatty
643 Acid and Retinol Binding Protein Orthologue from the Hookworm
644 *Ancylostoma Ceylanicum*. *Int. J. Parasitol.* **2009**, *39*, 1561–1571.

645 (12) Burbelo, P. D.; Leahy, H. P.; Iadarola, M. J.; Nutman, T. B. A
646 Four-Antigen Mixture for Rapid Assessment of *Onchocerca Volvulus*
647 Infection. *PLoS Neglected Trop. Dis.* **2009**, *3*, e438.

648 (13) Zhan, B.; Arumugam, S.; Kennedy, M.; Tricoche, N.; Lian, L.-
649 Y.; Asojo, O.; Bennuru, S.; Bottazzi, M.; Hotez, P. J.; Lustigman, S.;
650 Klei, T. R. Ligand Binding Properties of Two *Brugia Malayi* Fatty
651 Acid and Retinol (FAR) Binding Proteins and Their Vaccine

Efficacies against Challenge Infection in Gerbils. *PLoS Neglected* 652
Trop. Dis. **2018**, *12* (10), e0006772. 653

(14) Lal, P. G.; James, E. R. Onchocerca Retinol- and Ivermectin- 654
Binding Protein Activity. *Parasitology* **1996**, *112* (2), 221–225. 655

(15) Sanı, B.; Vaid, A. Specific Interaction of Ivermectin with 656
Retinol-Binding Protein from Filarial Parasites. *Biochem. J.* **1988**, *249*, 657
929–932. 658

(16) Vos, T.; et al. Global, Regional, and National Incidence, 659
Prevalence, and Years Lived with Disability for 328 Diseases and 660
Injuries for 195 Countries, 1990–2016: A Systematic Analysis for the 661
Global Burden of Disease Study. *Lancet* **2017**, *390* (10100), 1211– 662
1259. 663

(17) Loukas, A.; Hotez, P.; Diemert, D.; Yazdanbakhsh, M.; 664
McCarthy, J.; Correa-Oliveira, R.; Croese, J.; Bethony, J. Hookworm 665
Infection. *Nat. Rev. Dis Prim.* **2016**, *2* (1), 16088. 666

(18) Zonta, M.; Oyhenart, E.; Navone, G. Nutritional Status, Body 667
Composition, and Intestinal Parasitism among the Mbyá-Guarani 668
Communities of Misiones, Argentina. *Am. J. Hum Biol.* **2009**, *22* (2), 669
193–200. 670

(19) Daub, J.; Loukas, A.; Pritchard, D.; Blaxter, M. A Survey of 671
Genes Expressed in Adults of the Human Hookworm, *Necator* 672
Americanus. *Parasitology* **2000**, *120* (2), 171–184. 673

(20) Rey-Burusco, M.; Ibáñez-Shimabukuro, M.; Gabrielsen, M.; 674
Franchini, G.; Roe, A.; Griffiths, K.; Zhan, B.; Cooper, A.; Kennedy, 675
M. W.; Córscico, B.; Smith, B. O. Diversity in the Structures and 676
Ligand-Binding Sites of Nematode Fatty Acid and Retinol-Binding 677
Proteins Revealed by Na-FAR-1 from *Necator Americanus*. *Biochem.* 678
J. **2015**, *471*, 403–414. 679

(21) Jordanova, R.; Groves, M.; Kostova, E.; Woltersdorf, C.; 680
Liebau, E.; Tucker, P. Fatty Acid- and Retinoid-Binding Proteins 681
Have Distinct Binding Pockets for the Two Types of Cargo. *J. Biol.* 682
Chem. **2009**, *284* (51), 35818–35826. 683

(22) Storch, J.; McDermott, L. Structural and Functional Analysis of 684
Fatty Acid-Binding Proteins. *J. Lipid Res.* **2009**, *50* (Suppl), S126– 685
S131. 686

(23) Storch, J.; Corsico, B. The Emerging Functions and 687
Mechanisms of Mammalian Fatty Acid-Binding Proteins. *Annu. Rev.* 688
Nutr. **2008**, *28*, 73–95. 689

(24) Banaszak, L.; Winter, N.; Xu, Z.; Bernlohr, D.; Cowan, S.; 690
Jones, T. Lipid-Binding Proteins: A Family of Fatty Acid and Retinoid 691
Transport Proteins. *Adv. Protein Chem.* **1994**, *45*, 89–151. 692

(25) Stewart, J. The Cytoplasmic Fatty-Acid-Binding Proteins: 693
Thirty Years and Counting. *Cell. Mol. Life Sci.* **2000**, *57*, 1345–1359. 694

(26) Friedman, R.; Nachliel, E.; Gutman, M. Fatty Acid Binding 695
Proteins: Same Structure but Different Binding Mechanisms? 696
Molecular Dynamics Simulations of Intestinal Fatty Acid Binding 697
Protein. *Biophys. J.* **2006**, *90* (March), 1535–1545. 698

(27) Hotamisligil, G.; Bernlohr, D. Metabolic Functions of FABPs- 699
Mechanisms and Therapeutic Implications. *Nat. Rev. Endocrinol.* **700**
2015, *11* (10), 592–605. 701

(28) McDermott, L.; Cooper, A.; Kennedy, M. Novel Classes of 702
Fatty Acid and Retinol Binding Protein from Nematodes. *Mol. Cell.* 703
Biochem. **1999**, *192*, 69–75. 704

(29) Zimmerman, A. W.; Veerkamp, J. H. New Insights into the 705
Structure and Function of Fatty Acid-Binding Proteins. *Cell. Mol. Life* 706
Sci. **2002**, *59*, 1096–1116. 707

(30) Veerkamp, J.; Peeters, R.; RGHJ, M. Structural and Functional 708
Features of Different Types of Cytoplasmic Fatty Acid-Binding. 709
Biochim. Biophys. Acta, Lipids Lipid Metab. **1991**, *1081*, 1–24. 710

(31) Sha, R.; Kane, C.; Xu, Z.; Banaszak, L.; Bernlohr, D. 711
Modulation of Ligand Binding Affinity of the Adipocyte Lipid- 712
Binding Protein by Selective Mutation: Analysis in Vitro and in Situ. *J.* 713
Biol. Chem. **1993**, *268*, 7885–7892. 714

(32) Prinsen, C.; Veerkamp, J. Fatty Acid Binding and Conforma- 715
tional Stability of Mutants of Human Muscle Fatty Acid-Binding 716
Protein. *Biochem. J.* **1996**, *314*, 253–260. 717

(33) Jakoby, M.; Miller, K.; Toner, J.; Bauman, A.; Cheng, L.; Li, E.; 718
et al. Ligand-Protein Electrostatic Interactions Govern the Specificity 719

- 720 of Retinol- and Fatty Acid-Binding Proteins. *Biochemistry* **1993**, *32*,
721 872–878.
- 722 (34) Thumser, A.; Evans, C.; Worrall, A.; Wilton, D. Effect on
723 Ligand Binding of Arginine Mutations in Recombinant Rat Liver
724 Fatty Acid-Binding Protein. *Biochem. J.* **1994**, *297*, 103–107.
- 725 (35) Thumser, A.; Voysey, J.; Wilton, D. Mutations of Recombinant
726 Rat Liver Fatty Acid-Binding Protein at Residues 102 and 122 Alter
727 Its Structural Integrity and Affinity for Physiological Ligands. *Biochem.*
728 *J.* **1996**, *314*, 943–949.
- 729 (36) Laulumaa, S.; Nieminen, T.; Raasakka, A.; Krokengen, O.;
730 Safaryan, A.; Hallin, E.; Brysbaert, G.; Lensink, M.; Ruskamo, S.;
731 Vattulainen, I.; Kursula, P. Structure and Dynamics of a Human
732 Myelin Protein P2 Portal Region Mutant Indicate Opening of the β
733 Barrel in Fatty Acid Binding Proteins. *BMC Struct. Biol.* **2018**, *18* (8),
734 1–13.
- 735 (37) Hodsdon, M. E.; Cistola, D. P. Discrete Backbone Disorder in
736 the Nuclear Magnetic Resonance Structure of Apo Intestinal Fatty
737 Acid-Binding Protein: Implications for the Mechanism of Ligand
738 Entry. *Biochemistry* **1997**, *36*, 1450–1460.
- 739 (38) Friedman, R.; Nachliel, E.; Gutman, M. Molecular Dynamics
740 Simulations of the Adipocyte Lipid Binding Protein Reveal a Novel
741 Entry Site for the Ligand. *Biochemistry* **2005**, *44*, 4275–4283.
- 742 (39) Tsfadia, Y.; Friedman, R.; Kadmon, J.; Selzer, A.; Nachliel, E.;
743 Gutman, M. Molecular Dynamics Simulations of Palmitate Entry into
744 the Hydrophobic Pocket of the Fatty Acid Binding Protein. *FEBS Lett.*
745 **2007**, *581* (6), 1243–1247.
- 746 (40) Matsuoka, D.; Sugiyama, S.; Murata, M.; Matsuoka, S.
747 Molecular Dynamics Simulations of Heart-Type Fatty Acid Binding
748 Protein in Apo and Holo Forms, and Hydration Structure Analyses in
749 the Binding Cavity. *J. Phys. Chem. B* **2015**, *119* (1), 114–127.
- 750 (41) Laulumaa, S.; Nieminen, T.; Lehtimäki, M.; Aggarwal, S.;
751 Simons, M.; Koza, M. M.; Vattulainen, I.; Kursula, P.; Natali, F.
752 Dynamics of the Peripheral Membrane Protein P2 from Human
753 Myelin Measured by Neutron Scattering—A Comparison between
754 Wild-Type Protein and a Hinge Mutant. *PLoS One* **2015**, *10* (6),
755 e0128954.
- 756 (42) Guo, Y.; Duan, M.; Yang, M. The Observation of Ligand-
757 Binding-Relevant Open States of Fatty Acid Binding Protein by
758 Molecular Dynamics Simulations and a Markov State Model. *Int. J.*
759 *Mol. Sci.* **2019**, *20* (14), 3476.
- 760 (43) Andrew McCammon, J.; Harvey, S. C. *Dynamics of Proteins and*
761 *Nucleic Acids*; Cambridge University Press: Cambridge, U.K., 1987.
- 762 (44) Karplus, M.; Kuriyan, J. Molecular Dynamics and Protein
763 Function. *Proc. Natl. Acad. Sci. U. S. A.* **2005**, *102*, 6679–6685.
- 764 (45) Karplus, M.; McCammon, J. A. Molecular Dynamics
765 Simulations of Biomolecules. *Nat. Struct. Biol.* **2002**, *9*, 646–652.
- 766 (46) Brooks, C., III; Karplus, M.; Pettitt, B. M. *Proteins: A*
767 *Theoretical Perspective of Dynamics, Structure, and Thermodynamics*;
768 Prigogine, I., Rice, S. A., Eds.; John Wiley & Sons Ltd.: New York,
769 1987.
- 770 (47) Ichiye, T.; Karplus, M. Collective Motions in Proteins: A
771 Covariance Analysis of Atomic Fluctuations in Molecular Dynamics
772 and Normal Mode Simulations. *Proteins: Struct., Funct., Genet.* **1991**,
773 *11*, 205–217.
- 774 (48) Horiuchi, T.; Go, N. Projection of Monte Carlo and Molecular
775 Dynamics Trajectories onto the Normal Mode Axes: Human
776 Lysozyme. *Proteins: Struct., Funct., Genet.* **1991**, *10* (2), 106–116.
- 777 (49) van Aalten, D. M. F.; de Groot, B. L.; Findlay, J. B. C.;
778 Berendsen, H. J. C.; Amadei, A. A Comparison of Techniques for
779 Calculating Protein Essential Dynamics. *J. Comput. Chem.* **1997**, *18*
780 (2), 169–181.
- 781 (50) Jolliffe, I. T. *Principal Component Analysis*, 2nd ed.; Springer-
782 Verlag: Berlin, 2002.
- 783 (51) David, C. C.; Jacobs, D. J. *Protein Dynamics*; Livesay, D. R., Ed.;
784 *Methods in Molecular Biology*; Humana Press: Totowa, NJ, 2014;
785 Vol. 1084.
- 786 (52) Desdouts, N.; Nilges, M.; Blondel, A. Principal Component
787 Analysis Reveals Correlation of Cavities Evolution and Functional
788 Motions in Proteins. *J. Mol. Graphics Modell.* **2015**, *55*, 13–24.
- (53) Barletta, G. P.; Fernandez-Alberti, S. Protein Fluctuations and
789 Cavity Changes Relationship. *J. Chem. Theory Comput.* **2018**, *14* (2),
790 998–1008.
- (54) *Lipid Binding Proteins within Molecular and Cellular*
792 *Biochemistry*; Banaszak, L., Bernlohr, D. A., Eds.; Springer Science
793 +Business Media, B.V.: Berlin. 794
- (55) Hunter, N. H.; Bakula, B. C.; Bruce, C. D. Molecular Dynamics
795 Simulations of Apo and Holo Forms of Fatty Acid Binding Protein 5
796 and Cellular Retinoic Acid Binding Protein II Reveal Highly Mobile
797 Protein, Retinoic Acid Ligand, and Water Molecules. *J. Biomol. Struct.*
798 *Dyn.* **2018**, *36* (7), 1893–1907. 799
- (56) Rich, M.; Evans, J. S. Molecular Dynamics Simulations of
800 Adipocyte Lipid-Binding Protein: Effect of Electrostatics and Acyl
801 Chain Unsaturation. *Biochemistry* **1996**, *35* (5), 1506–1515. 802
- (57) Long, D.; Mu, Y.; Yang, D. Molecular Dynamics Simulation of
803 Ligand Dissociation from Liver Fatty Acid Binding Protein. *PLoS One*
804 **2009**, *4* (6), e6081. 805
- (58) Sivanesan, D.; Rajnarayanan, R.; Doherty, J.; Pattabiraman, N.
806 In-Silico Screening Using Flexible Ligand Binding Pockets: A
807 Molecular Dynamics-Based Approach. *J. Comput.-Aided Mol. Des.*
808 **2005**, *19* (4), 213–228. 809
- (59) Salomon-Ferrer, R.; Case, D.; Walker, R. An Overview of the
810 Amber Biomolecular Simulation Package. *WIREs Comput. Mol. Sci.*
811 **2013**, *3*, 198–210. 812
- (60) Case, D.; Cheatham, T. I.; Darden, T.; Gohlke, H.; Luo, R.;
813 Merz, K. J.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. The
814 Amber Biomolecular Simulation Programs. *J. Comput. Chem.* **2005**,
815 *26*, 1668–1688. 816
- (61) Berman, H.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. The
817 Protein Data Bank. *Nucleic Acids Res.* **2000**, *28*, 235–242. 818
- (62) Sacchettini, J.; Gordon, J.; Banaszak, L. Refined Apoprotein
819 Structure of Rat Intestinal Fatty Acid Binding Protein Produced in
820 *Escherichia Coli*. *Proc. Natl. Acad. Sci. U. S. A.* **1989**, *86* (20), 7736–
821 7740. 822
- (63) Sacchettini, J.; Gordon, J.; Banaszak, L. Crystal Structure of
823 Rat Intestinal Protein Refinement and Analysis of the *Escherichia*
824 *Coli*-Derived Protein with Bound Palmitate. *J. Mol. Biol.* **1989**, *208*,
825 327–339. 826
- (64) Hodsdon, M.; Ponder, J.; Cistola, D. The NMR Solution
827 Structure of Intestinal Fatty Acid-Binding Protein Complexed with
828 Palmitate: Application of a Novel Distance Geometry Algorithm. *J.*
829 *Mol. Biol.* **1996**, *264*, 585–602. 830
- (65) Ponder, J.; Case, D. Force Fields for Protein Simulations. *Adv.*
831 *Protein Chem.* **2003**, *66*, 27–85. 832
- (66) Maier, J.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser,
833 K.; Simmerling, C. Ff14SB: Improving the Accuracy of Protein Side
834 Chain and Backbone Parameters from Ff99SB. *J. Chem. Theory*
835 *Comput.* **2015**, *11*, 3696–3713. 836
- (67) Jorgensen, W.; Chandrasekhar, J.; Madura, J.; Impey, R.; Klein,
837 M. Comparison of Simple Potential Functions for Simulating Liquid
838 Water. *J. Chem. Phys.* **1983**, *79*, 926–935. 839
- (68) Amadei, A.; Linssen, A. B. M.; Berendsen, H. J. C. Essential
840 Dynamics of Proteins. *Proteins: Struct., Funct., Genet.* **1993**, *17* (4),
841 412–425. 842
- (69) Brooks, B.; Janezic, D.; Karplus, M. Harmonic Analysis of Large
843 Systems. I. Methodology. *J. Comput. Chem.* **1995**, *16* (12), 1522–
844 1542. 845
- (70) Monzon, A. M.; Zea, D. J.; Fornasari, M. S.; Saldaño, T. E.;
846 Fernandez-Alberti, S.; Tosatto, S. C. E.; Parisi, G. Conformational
847 Diversity Analysis Reveals Three Functional Mechanisms in Proteins.
848 *PLoS Comput. Biol.* **2017**, *13* (2), e1005398. 849
- (71) Chen, Z.; Qiao, Y.; Klimtchuk, E.; Hamilton, J. A.; Cai, J.; Lu,
850 C. Solution Structure and Backbone Dynamics of Human Liver Fatty
851 Acid Binding Protein: Fatty Acid Binding Revisited. *Biophys. J.* **2012**,
852 *102* (11), 2585–2594. 853
- (72) Hodsdon, M. E.; Cistola, D. P. Ligand Binding Alters the
854 Backbone Mobility of Intestinal Fatty Acid-Binding Protein as
855 Monitored by 15 N NMR Relaxation and 1 H Exchange †. *856*
Biochemistry **1997**, *36* (8), 2278–2290. 857

- 858 (73) Arighi, C.; Rossi, J.; Delfino, J. Temperature-Induced
859 Conformational Switch in Intestinal Fatty Acid Binding Protein
860 (IFABP) Revealing an Alternative Mode for Ligand Binding.
861 *Biochemistry* **2003**, *42* (24), 7539–7551.
- 862 (74) Curto, L.; Caramelo, J.; Delfino, J. Delta98delta, a Functional
863 All-Beta-Sheet Abridged Form of Intestinal Fatty Acid Binding
864 Protein. Delta98delta, a Functional All-Beta-Sheet Abridged Form of
865 Intestinal Fatty A. *Biochemistry* **2005**, *44* (42), 13847–13857.
- 866 (75) Porfido, J.; Alvite, G.; Silva, V.; Kennedy, M.; Esteves, A.;
867 Corsico, B. Direct Interaction between EgFABP1, a Fatty Acid
868 Binding Protein from *Echinococcus Granulosus*, and Phospholipid
869 Membranes. *PLoS Neglected Trop. Dis.* **2012**, *6* (11), e1893.
- 870 (76) Garofalo, A.; Kennedy, M.; Bradley, J. The FAR Proteins of
871 Parasitic Nematodes: Their Possible Involvement in the Pathogenesis
872 of Infection and the Use of *Caenorhabditis Elegans* as a Model
873 System to Evaluate Their Function. *Med. Microbiol. Immunol.* **2003**,
874 *192*, 47–52.
- 875 (77) Kennedy, M. The Nematode Polyprotein Allergens/Antigens.
876 *Parasitol. Today* **2000**, *16*, 373–380.
- 877 (78) Kennedy, M.; Scott, J.; Lo, S.; Beauchamp, J.; McManus, D. Sj-
878 FABPcfatty- Acid-Binding Protein of the Human Blood Fluke
879 *Schistosoma Japonicum*: Structural and Functional Characterization
880 and Unusual Solvent Exposure of a Portal-Proximal Tryptophan
881 Residue. *Biochem. J.* **2000**, *349*, 377–384.